Can This #Gepant be an Effective Preventive Treatment Option for Tough to Treat Episodic #Migraine?

A study in the Lancet found one oral gepant to be safe and effective in people with episodic migraine who have failed two to four classes of preventive treatments. Molly O'Brien explains in this Migraine Minute News Update.

Transcript 👇
New information from the ELEVATE Study shows that 60 mg of Atogepant– sold under brand name Qulipta- is safe, effective, and well tolerated as a preventive treatment in people with tough to treat episodic migraine.

The study looked at Atogepant as a preventive option for people with episodic migraine – who didn’t respond to two to four classes of oral preventive treatments.

Over the course of 3 months, people who took 60 mg once per day saw a significant drop in mean monthly migraine days compared to placebo.